UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines

ACS nano, 2020-07, Vol.14 (7), p.7682-7688

2020

Volltextzugriff (PDF)

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

Drug resistance updates, 2016-11, Vol.29, p.90-106

2016

Volltextzugriff (PDF)

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention

Advanced drug delivery reviews, 2011-09, Vol.63 (12), p.1020-1030

2011

Volltextzugriff (PDF)

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes

Anti-cancer drugs, 2015-03, Vol.26 (3), p.241-258

2015

Volltextzugriff (PDF)

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

Seminars in cancer biology, 2021-01, Vol.68, p.175-185

2021

Volltextzugriff (PDF)

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy

Frontiers in immunology, 2017-04, Vol.8, p.416-416

2017

Volltextzugriff (PDF)

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8), p.2412-2417

2013

Volltextzugriff (PDF)

Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas

Molecular cancer therapeutics, 2024-07, p.OF1-OF13

2024

Volltextzugriff (PDF)

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

ACS nano, 2017-01, Vol.11 (1), p.12-18

2017

Volltextzugriff (PDF)

Translational considerations in nanomedicine: The oncology perspective

Advanced drug delivery reviews, 2020, Vol.158, p.140-157

2020

Volltextzugriff (PDF)

A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1049-1049

2021

Volltextzugriff (PDF)

Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy

European journal of pharmaceutical sciences, 2012-03, Vol.45 (4), p.388-398

2012

Volltextzugriff (PDF)

Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside

Advanced drug delivery reviews, 2020, Vol.154-155, p.13-26

2020

Volltextzugriff (PDF)

Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity

Journal of controlled release, 2013-05, Vol.167 (3), p.265-275

2013

Volltextzugriff (PDF)

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate

Journal of controlled release, 2018-02, Vol.271, p.139-148

2018

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Cancer investigation, 2001, Vol.19 (4), p.424-436

Gabizon, Alberto A.

2001

Volltextzugriff (PDF)

Preclinical evaluation of Promitil®, a radiation-responsive liposomal formulation of mitomycin C prodrug, in chemoradiotherapy

International journal of radiation oncology, biology, physics, 2016-11, Vol.96 (3), p.547-555

2016

Volltextzugriff (PDF)

Pros and Cons of the Liposome Platform in Cancer Drug Targeting

Journal of liposome research, 2006-01, Vol.16 (3), p.175-183

2006

Volltextzugriff (PDF)

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses

Nanomedicine, 2015-02, Vol.11 (2), p.259-262

2015

Volltextzugriff (PDF)

Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage

Journal of controlled release, 2009-06, Vol.136 (2), p.155-160

2009

Volltextzugriff (PDF)

Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients

Investigational new drugs, 2020-10, Vol.38 (5), p.1411-1420

2020

Volltextzugriff (PDF)

Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model

Biomolecules (Basel, Switzerland), 2023-08, Vol.13 (9), p.1309

2023

Volltextzugriff (PDF)

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models

Cancer chemotherapy and pharmacology, 2010-05, Vol.66 (1), p.43-52

2010

Volltextzugriff (PDF)

Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids

PloS one, 2011-10, Vol.6 (10), p.e25721

2011

Volltextzugriff (PDF)

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience

Frontiers in oncology, 2018-11, Vol.8, p.544

2018

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(151)

Publikationsform

Sprache

Englisch
(158)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(96)
Humans
(72)
Female
(56)
Oncology
(53)
Animals
(48)
Liposomes
(47)
Pharmacology & Pharmacy
(46)
Biological And Medical Sciences
(42)
Medical Sciences
(41)
Doxorubicin - Administration & Dosage
(35)
Mice
(35)
Pharmacology. Drug Treatments
(35)
Chemotherapy
(31)
Doxorubicin
(30)
Antineoplastic Agents
(29)
Liposome
(28)
Middle Aged
(22)
Chemistry
(21)
Aged
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

Translational considerations in nanomedicine: The oncology perspective

A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer

Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy

Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside

Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Preclinical evaluation of Promitil®, a radiation-responsive liposomal formulation of mitomycin C prodrug, in chemoradiotherapy

Pros and Cons of the Liposome Platform in Cancer Drug Targeting

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses

Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage

Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients

Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models

Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids

Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience

Suchergebnisse filtern